Check Cap Ltd
Check Cap Ltd operates in the healthcare sector, specifically within the biotechnology and medical research industry, focusing on pharmaceuticals and medical research.
Business. Check Cap Ltd (MBAI.O) is a biotechnology and medical research company engaged in pharmaceuticals and medical research activities. The firm operates within the healthcare sector, specifically focusing on the development and sale of pharmaceutical products. Check Cap Ltd is headquartered in Israel and is primarily listed on the NASDAQ stock exchange. No specific operating segments or geographic revenue breakdowns are disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Check Cap Ltd (MBAI.O) is a biotechnology and medical research company engaged in pharmaceuticals and medical research activities. The firm operates within the healthcare sector, specifically focusing on the development and sale of pharmaceutical products. Check Cap Ltd is headquartered in Israel and is primarily listed on the NASDAQ stock exchange. No specific operating segments or geographic revenue breakdowns are disclosed in the available data.
Check Cap Ltd has a market price of $1.79 and a market cap of $12,566,698.58, indicating a relatively small market capitalization. The company's financial snapshot shows that the number of shares outstanding is the same for both basic and diluted shares, at 7,020,502, suggesting no immediate dilution risk.
The company's profitability is currently negative, as evidenced by the last actual EPS of -3.00, which indicates a loss per share. This loss per share is a significant concern when compared to industry standards, as it suggests the company is not generating positive returns for its shareholders at this time.
There is no detailed information provided on the company's segments or geographic exposure, which limits the ability to assess revenue concentration or diversification. Without this data, it is difficult to determine the extent to which the company's performance is tied to specific markets or product lines.
The company's growth trajectory is not clearly defined, as there is no outlook data provided for the current or next fiscal year. The absence of growth projections makes it challenging to assess the company's future performance or potential for expansion.
The risk assessment indicates that liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents. This lack of information is a red flag for investors, as it suggests that the company's ability to meet its short-term obligations is uncertain.
Recent events or filings that could impact the company's operations or financial status are not detailed in the provided data. This absence of recent events makes it difficult to gauge the company's current situation or any potential changes that may affect its performance.
- Check Cap Ltd is a small-cap company in the biotechnology and medical research industry.
- The company is currently reporting a loss per share, indicating poor profitability.
- There is no immediate dilution risk as the number of basic and diluted shares is the same.
- The company's liquidity risk could not be assessed due to insufficient data.
- The company's growth trajectory and future performance are unclear without additional outlook data.
- **margin_outlook_rationale**: The company's margin outlook is negative due to the reported loss per share.
- **rd_outlook_rationale**: There is no specific information provided on the company's research and development outlook.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Free cash flow +182,9% YoY.
- ▍Free cash flow +182,9% YoY
Operating income −34,5% YoY; Net income −43,1% YoY.
- ▍Operating income −34,5% YoY
- ▍Net income −43,1% YoY
- ▍Free cash flow −43,3% YoY
Operating income +3,7% YoY; Net income +8,1% YoY.
- ▍Operating income +3,7% YoY
- ▍Net income +8,1% YoY
- ▍Free cash flow +9,1% YoY
Operating income -$17.3M.
- ▍Operating income -$17.3M
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Check Cap Ltd Market data — financials · 2026-05-28
- Check Cap Ltd Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 0.05xDerived (calculated)
- Return on equity (FY 2025-12-31): 120.5%Derived (calculated)
- Return on assets (FY 2025-12-31): 55.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 116.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 99.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 115.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 337.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 115.3%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2023-12-31): -100.0%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 74.9%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 1,885.7%Derived (calculated)
- EPS (basic) (annual): USD-PER-SHARES 1SEC XBRL filing
- Net income (annual): USD 4.14MSEC XBRL filing
- Operating cash flow (annual): USD -46KSEC XBRL filing
- Shares outstanding (annual): 7.02MSEC XBRL filing
- Current assets (annual): USD 219KSEC XBRL filing
- Shareholders' equity (annual): USD 3.44MSEC XBRL filing
- Total assets (annual): USD 7.49MSEC XBRL filing
- Current liabilities (annual): USD 4.05MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 1SEC XBRL filing
- Cash & equivalents (annual): USD 2KSEC XBRL filing
- Operating income (annual): USD -2.37MSEC XBRL filing
- EPS (diluted) (YoY) (2024-12-31 vs 2023-12-31): -43.3%Derived (calculated)
- Shareholders' equity (YoY) (2024-12-31 vs 2023-12-31): -106.1%Derived (calculated)